Nadeem A. Vellore

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 366 citations · Full text

Medicine, Molecular Biology, Oncology +7

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 245 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <i>ROS1</i> -Rearranged Lung Cancer

Alexander Drilon, Romel Somwar, Jacob P. Wagner et al. · Clinical Cancer Research · 2015 · 167 citations · Full text

Medicine, Oncology, Pharmacology +16

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Anna M. Eiring, Brent D. G. Page, Ira L. Kraft et al. · Leukemia · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacology +12

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Monika A. Davare, Nadeem A. Vellore, Jacob P. Wagner et al. · Proceedings of the National Academy of Sciences · 2015 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17